|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Aurora-A alone or in combination with the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA), did not result in SCC formation in Aurora-AGS mice.
|
19738056 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AURKA gene amplification is a common genetic aberration in breast cancer, especially in tumors displaying basal-like phenotype.
|
20043089 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The amplification and over-expression of STK15 is common in neoplasia but the functional and clinical impact of STK15 in OSCC remains poorly understood.
|
20597069 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Principal common CNAs were the well known MYC-associated gain and RB1/INTS6-associated loss that occurred in all mouse and human tumor groups, and the AURKA-associated gain occurred in BRCA2-related tumors from both species.
|
20735817 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results indicate that in NSCLC AURKA over-expression is restricted to specific subtypes and poorly differentiated tumors.
|
21718475 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with high AURKA-CN tumours had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS wild-type tumours (median OS not reached vs 18.8 months, P=0.003).
|
22240781 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PTPRD has a tumor suppressor function in neuroblastoma through AURKA dephosphorylation and destabilization and a downstream destabilization of MYCN protein, representing a novel mechanism for the function of PTPRD in neuroblastoma.
|
22305495 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, only tumor size (P = 0.017), mitotic count (P = 0.007), and AURKA expression (P = 0.039) were identified as independent unfavorable prognostic factors for RFS in multivariate analysis.
|
22588468 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By using the AGS, FLO-1, and OE33 UGC cell lines, which have constitutive AURKA overexpression and variable tumor protein 53 (p53) status, significantly enhanced inhibition of cancer cell survival was observed with alisertib and docetaxel treatment in combination (P < .001), compared with single-agent treatments.
|
22972611 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, AURKA correlated with the proliferation metagene (R=0.880; P<0.001), showed a positive association with grade (P<0.001), tumor size (P<0.001) and HER2 (P<0.001), and was inversely associated with ER status (P<0.001).
|
23186136 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our data indicate that AURKA is a rationale therapeutic target for MPNST and tumour cell responses to AKI, which include differentiation, are modulated by the abundance of HMMR/RHAMM.
|
23328114 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
AURKA and MYCN amplifications may be prognostic and predictive biomarkers, as they are harbingers of tumors at risk of progressing to t-NEPC after hormonal therapy.
|
23358695 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Knockdown of AURKA expression and MLN8237 induced the growth inhibition of primary cultured cells established from patients' OSCC tumors.
|
23481312 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that AURKA and AURKB overexpression in pediatric ACT may be related to more aggressive disease and the inhibition of these proteins could be an interesting approach for the treatment of these tumors.
|
23788275 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of AURKA also reduced growth of xenograft tumors from human gastric cancer cells in mice and reversed the development of gastric tumors in Tff1(-/-) mice.
|
23993973 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of AURKA in CRCLM was correlated to its expression in corresponding primary tumour (P<0.01).
|
24104968 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression profiling revealed that REST not only acts to repress neuronal genes but also genes involved in cell cycle progression, including Aurora Kinase A, that has previously been implicated in the growth of NE-like castration-resistant tumors.
|
24163104 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Silencing of Aurora kinase A by RNA interference inhibits tumor growth in human osteosarcoma cells by inducing apoptosis and G2/M cell cycle arrest.
|
24452445 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We find that miR-199a-3p agomir inhibits aurora kinase A and attenuates xenograft tumor growth of PCa.
|
24631181 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aurora kinase A (AURKA), a member of the serine/threonine kinase family, is overexpressed across many types of human tumors.
|
24841948 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In ductal breast cancer, AURKA overexpression is strongly associated with the tumor grade and is therefore of prognostic value for the progression of the disease.
|
24876664 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This phenotype is induced by overexpression of the oncogene AURKA or by loss of the tumour suppressor gene CHK2, a genetic constitution found in 73% of human colorectal cancers.
|
24976383 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study showed that functional SNPs in the STK15 gene are associated with ESCC in a Mongolian population and up-regulation of STK15 mRNAoccurs in ESCC tumors compared adjacent normal tissues.
|
25124567 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
When histologically similar cases with and without AURKA amplification were compared, this gene alteration was associated with larger extent of Paneth cell-like NED identified at magnification ×20 (P = .015), higher percentage of Paneth cell-like NED throughout the tumor nodule (P = .033), ductal features (P = .02), and higher overall Gleason grade (P = .039).
|
25128228 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Blocking Aurka in an orthotopic model significantly impairs tumor growth in mice.
|
25284017 |
2015 |